Abstract
Cytomegalovirus (CMV) is a leading cause of congenital infection worldwide and therefore is recognized as an important target for vaccine development. Data from natural infections and work done with animal models, including models of congenital infection, provide the rationale for their development. CMV vaccine evaluations were begun in the mid-1970’s with an attenuated live virus vaccine, Towne, but this vaccine has not consistently provided protection. Most recently, data from a trial with a subunit glycoprotein B (gB) vaccine administered with the adjuvant MF59 became available. This trial, conducted in post-partum women, demonstrated that the vaccine decreased CMV infections, increasing optimism that a protective CMV vaccine could be developed. Other approaches for CMV that have entered clinical trials include replicons, DNA vaccines, prime boost strategies, and chimeric live viruses. The replicon vaccine included gB and the T cell targets phosphoprotein (pp)65 and Immediate Early (IE)1 while the DNA vaccine was given with a new adjuvant and included gB and pp65. The optimal composition for a CMV vaccine remains to be defined but trials continue with the gB vaccine and others.
Keywords: Cytomegalovirus, congenital infection, replicons, DNA vaccines, chimeric, vectors, glycoprotein B (gB) vaccine, natural infections, vaccine evaluations, prime boost strategies, asymptomatic, immunosenescence, protective immune response, cytokines, neutralizing antibodies
Infectious Disorders - Drug Targets
Title: Vaccines for Cytomegalovirus
Volume: 11 Issue: 5
Author(s): D. I. Bernstein
Affiliation:
Keywords: Cytomegalovirus, congenital infection, replicons, DNA vaccines, chimeric, vectors, glycoprotein B (gB) vaccine, natural infections, vaccine evaluations, prime boost strategies, asymptomatic, immunosenescence, protective immune response, cytokines, neutralizing antibodies
Abstract: Cytomegalovirus (CMV) is a leading cause of congenital infection worldwide and therefore is recognized as an important target for vaccine development. Data from natural infections and work done with animal models, including models of congenital infection, provide the rationale for their development. CMV vaccine evaluations were begun in the mid-1970’s with an attenuated live virus vaccine, Towne, but this vaccine has not consistently provided protection. Most recently, data from a trial with a subunit glycoprotein B (gB) vaccine administered with the adjuvant MF59 became available. This trial, conducted in post-partum women, demonstrated that the vaccine decreased CMV infections, increasing optimism that a protective CMV vaccine could be developed. Other approaches for CMV that have entered clinical trials include replicons, DNA vaccines, prime boost strategies, and chimeric live viruses. The replicon vaccine included gB and the T cell targets phosphoprotein (pp)65 and Immediate Early (IE)1 while the DNA vaccine was given with a new adjuvant and included gB and pp65. The optimal composition for a CMV vaccine remains to be defined but trials continue with the gB vaccine and others.
Export Options
About this article
Cite this article as:
I. Bernstein D., Vaccines for Cytomegalovirus, Infectious Disorders - Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/187152611797636695
DOI https://dx.doi.org/10.2174/187152611797636695 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens
Current Drug Metabolism Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry Radiosynthesis of 2-deoxy-2-[18F]fluorothymidine ([18F]FT), a Putative PET Agent for Imaging HSV-TK Expression
Current Radiopharmaceuticals Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target
Current Medicinal Chemistry Astrocytes as an HIV Reservoir: Mechanism of HIV Infection
Current HIV Research The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Neuroprotective Therapy for HIV Dementia
Current HIV Research Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Modulation of γ<sub>2</sub>-MSH Hepatoprotection by Antisense Peptides and Melanocortin Subtype 3 and 4 Receptor Antagonists
Medicinal Chemistry Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery